Drugs / Irinotecan Hydrochloride Liposome
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07183865 | Mar 2025 → Mar 2030 expected | rectal cancer | Fudan University | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT07582315 Comparator | Jul 2026 → Dec 2028 expected | biliary tract cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07606599 Comparator | May 2026 → Dec 2028 expected | biliary tract cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irinotecan Hydrochloride Liposome | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07183865 ↗ |
| Route | Intravenous | “70mg/m2 (UGT1A1\*28 6/6) or 55mg/m2 (UGT1A1\*28 6/7), IV, q2w” NCT07183865 ↗ |